Articles tagged with Hepatocellular Carcinoma
Researchers used functional MRI to measure tumor activity during chemoembolization, finding that changes in ADC values can predict anatomical tumor response. Early knowledge of HCC response is crucial for determining treatment success and patient prognosis.
Researchers at Thomas Jefferson University found that antiviral therapy prevents HCC recurrence and extends survival in CHB patients. The median survival was 60 months for those receiving antiviral therapy, compared to 12.5 months for those not receiving it.
A study published in Hepatology found that fewer than 20% of patients with cirrhosis and hepatocellular carcinoma received regular surveillance. Despite high-risk patients being recommended for HCC surveillance, population-based studies indicate only 11% are diagnosed early enough to receive potentially curative treatments.
Researchers found that sustained virologic response (SVR) prevents esophageal varices in patients with compensated hepatitis C (HCV)-induced cirrhosis. This study suggests that endoscopic surveillance can be safely delayed or avoided in these patients, reducing unnecessary invasive procedures.
A recent study by the Cleveland Clinic reveals that patients with NASH-induced cirrhosis are at an equal risk of developing hepatocellular carcinoma as those with HCV-cirrhosis. Researchers found three key factors associated with HCC development in the NASH population: older age, higher BMI, and lifetime alcohol consumption.
Patients with chronic hepatitis C virus infection have a higher risk of developing hepatocellular carcinoma (HCC) if they experience increased insulin resistance, regardless of their presence of type 2 diabetes mellitus. Insulin resistance is associated with fibrosis progression and poor antiviral therapy responses in these patients.
A study published in the World Journal of Gastroenterology found that antithromboembolic prophylaxis is not necessary for cirrhotic patients undergoing liver resection, as the risk of venous thromboembolism is low. However, the presence of esophageal varices may contraindicate prophylaxis due to increased risk of postoperative hemorrhage.
A patient with past history of hepatocellular carcinoma (HCC) presented with renal tumor 12 years later, revealing solitary recurrence of the initial HCC. This case emphasizes the need for early diagnosis of metastatic HCC to alter treatment planning and improve patient outcomes.
Virginia Commonwealth University researchers identified a new tumor-promoting gene called LSF, which is significantly higher in more than 90% of patients with liver cancer compared to healthy individuals. Inhibiting LSF may reverse the aggressive properties of human liver cancer cells.
A large patient cohort study found that genomic-based portraits can predict liver cancer recurrence. Two gene signatures were identified to identify patients with poor disease outcomes, enabling preventive therapies. The study also highlights potential therapeutic targets for adjuvant treatment following surgical intervention.
A study published in the World Journal of Gastroenterology found that hepatectomy is an effective treatment for caudate lobe HCC, with subsegmental location and liver cirrhosis affecting long-term survival. Extended hepatectomy was recommended to achieve adequate tumor margins and improve survival rates.
A study found that sirolimus-based immunosuppression significantly increases survival rates for post-transplant liver cancer patients, while radiofrequency ablation shows promise for very early-stage HCC treatment.
The US medical community has developed new transplant criteria for patients with liver cancer, aiming to ensure equitable organ allocation. The guidelines prioritize candidates based on tumor size, alpha-fetoprotein levels, and MELD scores, while also considering locoregional therapy and down-staging.
A new study has found that current biomarkers des-gamma-carboxy prothrombin (DCP) and alpha fetoprotein (AFP) are not optimal for early detection of liver cancer. The study suggests that combining both markers can increase sensitivity but decrease specificity, indicating a need for further investigation.
A new study reports successful laparoscopic hepatectomy in an aged cirrhotic patient with HCC recurrence. The procedure resulted in smaller wounds, less blood loss, and faster recovery. Further studies are needed to fully evaluate the role of laparoscopic surgery in HCC management.
Research at the University of California, San Diego, reveals that obesity is a tumor-promoting factor for liver cancer, primarily through chronic inflammation caused by cytokines like IL-6 and TNF. This effect may be preventable with anti-TNF drugs, which also reduce liver fat accumulation.
Researchers identified a new tumor suppressor gene, SCARA5, that is frequently silenced in human liver cancer, and also found genetic variants in the HSPB7 gene linked to heart failure. The study suggests that these genetic changes can contribute to cancer development and progression.
Researchers have identified SCARA5 as a candidate tumor suppressor gene in human hepatocellular carcinoma (HCC), a form of liver cancer. Genetic and epigenetic silencing of SCARA5 is linked to aggressive disease, including tumor invasion into blood vessels.
Researchers discovered Snail and Twist are the major inducers of EMT in HCC, associated with reduced E-cadherin function and larger tumor size. The study provides essential information for determining liver cancer prognosis and identifying potential new treatments.
A recent study found a causal link between aberrant sustained hepatic LT?R signaling and the development of chronic hepatitis-induced liver cancer. Elevated lymphotoxin expression in the liver leads to inflammation and cancer progression.
A 20-year study revealed a significant drop in liver cancer cases among vaccinated 6- to 19-year-olds. The universal vaccination program in Taiwan has been shown to extend its effectiveness into young adulthood.
Patients who exhibited skin rash from lapatinib showed a greater tumor response and longer survival, while others experienced no benefit. The study suggests that larger trials with more responsive patients may show a definite survival benefit.
Research finds sequential use of transarterial chemoembolization (TACE) and percutaneous cryosurgery can treat more HCC patients, even those with larger tumors. This minimally invasive technique improves patient survival times and reduces surgical complications.
Studies reveal that hepatitis C virus carriers have a significant increase in mortality, with liver-related deaths being the leading cause. The research found that monitoring HCV load and ALT levels may be crucial for identifying high-risk individuals, particularly older carriers who are less responsive to treatment.
A study found that S-adenosylmethionine (SAMe) prevents the formation of hepatocellular carcinoma (HCC) in rats, with a 1cm tumor reduced in size after treatment. However, high doses were not sufficient to treat established HCC cases, as the liver compensates for SAMe accumulation by metabolizing it.
A large meta-analysis found certain HBV DNA mutations associated with HCC development and more prevalent in chronic HBV infection progression. The study may help predict liver cancer risk in patients with HBV infections.
The presence of multiple portal vein invasion (PVI) is a significantly poor prognostic factor for hepatocellular carcinoma. Anatomical resection is recommended for patients with HCC and PVI-M, while non-anatomical resection may lead to poorer disease-free survival.
Researchers evaluated percutaneous radiofrequency ablation (PAA) as an alternative to conventional RFA in treating hypervascular HCC. The study found that PAA significantly reduced post-RFA recurrence and improved treatment outcomes, making it a promising new approach for this patient population.
A DNA vector-based approach silences STAT3, inhibiting HCC cell growth and inducing apoptosis. This study demonstrates RNAi's therapeutic potential in treating HCC by targeting the STAT3 gene.
A study published in the World Journal of Gastroenterology found that type 2 diabetes mellitus is an independent risk factor for hepatocellular carcinoma. The research revealed a direct association between HCC and insulin/sulphanylureas treatment, as well as an inverse relationship with metformin therapy.
Researchers found that a high-fat diet increases the risk of liver cancer in genetically susceptible mice, while switching to a low-fat diet reverses this outcome. The study could lead to screening methods for precancerous conditions and cancer prevention strategies related to obesity.
Two studies published in Gastroenterology found that statin use is associated with a significant reduction in the risk of hepatocellular carcinoma (HCC) among patients with diabetes. Additionally, statins appear to reduce the risk of cholecystectomy, surgical removal of the gallbladder, in women.
A new study published in Hepatology found that women with a history of hypothyroidism are at a significantly higher risk of developing liver cancer. The study revealed that subjects with a prior history of hypothyroidism had twice the risk of liver cancer, particularly for females, and those who had it for over 10 years had a threefold...
A new study shows radioembolisation to be a safe and effective treatment for patients with advanced HCC, achieving partial response rates of up to 80% and comparable survival rates to systemic therapy. The technique may offer a novel palliative therapeutic approach for those with limited options.
Researchers found that combining vitamin K with sorafenib reduced the need for higher doses of sorafenib by more than 50% in both pancreas cancer and hepatocellular carcinoma studies. This combination also inhibited tumor growth and induced cell death, offering a potential cure strategy.
A prospective cohort study found TACE treatments to be well-tolerated and safe for asymptomatic patients with preserved liver function, with a high HCC progression-free survival probability. The study's results support the efficacy of selective TACE in prolonging life expectancy and confirm its role as a key treatment option.
A rare case of liver cell adenoma (LCA) was reported in a woman without typical background, showing sequential alteration in radiological findings suggesting well-differentiated HCC. The patient underwent partial hepatectomy and pathological findings confirmed the diagnosis of LCA.
Research identifies GABRA3 subunit overexpression in hepatocellular carcinoma (HCC) cells, promoting cell growth and proliferation. The study suggests that targeting the GABAergic system may be a promising approach for HCC diagnosis and treatment.
Researchers at Virginia Commonwealth University identified a gene, AEG-1, that plays a key role in regulating liver cancer progression. The study found that AEG-1 expression increases as the tumor becomes more aggressive and is involved in invasion, metastasis, resistance to chemotherapy, and other processes.
Researchers identified AEG1 as a gene and protein crucial for HCC progression, suggesting targeting it may be a new therapeutic strategy. Overexpression of AEG1 accelerated tumor growth in mouse models.
Researchers have identified a gene AEG1 that plays a key role in human liver cancer progression. Targeting this gene may provide new therapeutic options for treating liver cancer. Additionally, adenosine signaling has been linked to alcohol-induced fatty liver disease in mice, suggesting potential treatments involving adenosine receptors.
A new study identifies Capn4 as a key molecule associated with liver cancer recurrence and metastasis after liver transplantation. The findings suggest that Capn4 expression is correlated with clinical outcomes and could be used as a prognostic marker for diagnosis.
A study found that HCC cases with AIH and PBC have four clinical features: shorter survival intervals, more men affected, and liver failure as primary cause of death. The research highlights these common characteristics in HCC associated with AIH and PBC.
A phase III trial found sorafenib to be effective in increasing overall survival by 6.5 months compared to 4.2 months in the placebo group, and prolonged time to progression and disease control rate. Sorafenib was generally well-tolerated with some side effects.
A new set of criteria, called Up-to-seven, has been identified to help select patients with hepatocellular carcinoma (HCC) who can benefit from liver transplantation. The criteria assess the size and number of tumors, and suggest that some patients who previously did not meet the Milan criteria may still be good candidates for transplant.
Researchers have developed approaches to visualize eosinophils in real-time, which may help diagnose asthma and assess treatment efficacy. Additionally, genetic defects underlying two kidney conditions and a type of liver cancer have been identified, suggesting potential therapeutic targets for these diseases.
This study investigates the correlation between changes in CT perfusion parameters pre- and post-TACE treatment of HCC and various responses to TACE. The findings suggest that CT perfusion imaging is a feasible technique for monitoring response of HCC to TACE, indicating its potential as an adjunctive tool in clinical practice.
A large population-based case-control study found that patients with type 2 diabetes mellitus (DM2) have a significantly increased risk of hepatocellular carcinoma (HCC), independent of cofactors. The study suggests that DM2 may be a concourse rather than merely a consequence of the liver tumor.
Researchers found MRN can be differentiated from HCC using CT/MRI features, including typical hyperdense appearance and lack of enhancement. Liver biopsy can be avoided if supported by these images, reducing the need for repeated biopsies.
A new therapeutic option for human hepatocyte cancer has been identified, leveraging parvovirus H-1 oncolytic therapy. The treatment targets p53-deficient tumors and induces apoptosis, potentially overcoming resistance to genotoxic agents.
A previously asymptomatic man developed a huge peritoneal mass after spontaneous rupture of hepatocellular carcinoma. The association between the metastatic tumor and viral infection, AFP level, or age was lacking due to few reported cases.
A study published in World Journal of Gastroenterology found high circulating D-dimer levels associated with ascites presence in liver cirrhosis patients. Ascites depletion may prevent bleeding complications. High D-dimer levels also linked to hepatocellular carcinoma (HCC) in cirrhotic patients without ascites.
A randomized controlled trial found that combining TACE and RFA therapies resulted in longer survival times for patients with large liver cancer tumors. The therapy improved survival by slowing tumor progression and blocking the blood supply to the tumor.
Research found prokineticin 2/Bv8 is downregulated in human hepatocellular carcinoma, but expressed in liver resident macrophages, suggesting a role in Kupffer cell physiology.
A study published in the World Journal of Gastroenterology found that Fu-Zheng-Jie-Du-Decoction increased PTEN expression in hepatocellular carcinoma, suggesting a promising future for TCM as a combined therapy. The decoction was shown to decrease tumor metastasis and improve survival rates compared to chemotherapy.
Researchers found that Gas6 protein increases cell signaling in response to Epo treatment and treats both chronic and acute anemia in mice. Additionally, mice deficient in Gas6 have decreased sensitivity to Epo and reduced ability to recover from anemia.
A specific gene variation appears to significantly increase the risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis. Researchers found that elevated EGF levels and activation of the EGFR receptor were associated with a higher risk of HCC in patients with at least one copy of the G allele.
A study found massive necrosis after trans-catheter treatment for liver cancer to be more common when a tumor capsule is present. Patients with tumors between 2-6 cm, low CLIP scores, and no constitutional syndrome were most likely to experience this outcome.
A 24-week course of interferon-alpha therapy after curative treatment for HCV-associated HCC significantly reduces tumor recurrence rates and improves patient survival compared to those without interferon therapy. Patients who achieved a sustained virological response also exhibit improved liver function and prolonged overall survival.
A new potential therapeutic target for early-stage hepatocellular carcinoma has been identified through a study published in the World Journal of Gastroenterology. Survivin protein expression was found to be elevated in 64.7% of HCC specimens, suggesting its role as a marker for diagnosis and treatment.